Despite the strong rationale based upon CDKN2A common alterations in PDAC and strong preclinical data, the CDK inhibitor palbociclib did not have meaningful clinical activity in CDKN2A-mutated advanced pancreatic cancer in a previous study (28), and palbociclib plus nab-paclitaxel did not reach the expected level of efficacy in our study. Here, CDKN2A is linked to familial pancreatic carcinoma.